ATOH1 and small cell lung carcinoma: Compared to other molecular subtype CDXs (31 SCLC-A, 25 patients; 2 SCLC-N, 2 patients), which displayed variable chemotherapy responses, all 4 ATOH1 CDXs (3 patients) were the most chemoresistant, scoring as PD1 (Figure 1G; Fisher’s exact test, p = 0.0049; Table S1).